Pharmarise Holdings Corporation
Symboli: 2796.T
JPX
659
JPYMarkkinahinta tänään
24.8104
P/E-suhde
-0.9523
PEG-suhde
7.41B
MRK Cap
- 0.02%
DIV Tuotto
Pharmarise Holdings Corporation (2796-T) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4742 | 3991 | 4604 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | -1926 | -2079 | -2427 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 605 | 479 | 926 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 2290 | 2302 | 2587 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 317 | 315 | 260 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 11372 | 10878 | 10546 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 6007 | 6355 | 6432 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2748 | 3220 | 4025 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 501 | 408 | 438 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3249 | 3628 | 4463 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 2008 | 2139 | 2488 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 778 | 741 | 786 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 4 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 12042 | 12863 | 14173 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 7 | 5 | 5 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 4252 | 4109 | 4609 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3677 | 2490 | 2819 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 333 | 429 | 573 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5461 | 7422 | 7878 | ||||||||||||||||
Deferred Revenue Non Current | 0 | -42 | -31 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 747 | 691 | 645 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 6600 | 8571 | 9001 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 432 | 551 | 700 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 16435 | 17048 | 18393 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 1298 | 1274 | 1251 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4014 | 3811 | 3494 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 226 | 203 | 208 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1343 | 1319 | 1268 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6881 | 6607 | 6221 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 105 | 91 | 110 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 6986 | 6698 | 6331 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 82 | 60 | 61 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 9138 | 9912 | 10697 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | 4396 | 5921 | 6093 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 513 | -1465 | -139 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 482 | -1319 | 365 | ||||||||||||||||
cash-flows.row.inventory | 0 | 68 | 286 | 56 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 13 | -500 | -582 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -50 | 68 | 22 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -266 | -452 | -462 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -180 | 2 | -116 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -2 | -2 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 383 | 12 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 19 | -209 | -418 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -703 | -292 | -1076 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2419 | -2636 | -2857 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 1737 | 2199 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -36 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -131 | -131 | -129 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1478 | -2 | 95 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -1072 | -1034 | -728 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2 | 0 | -1 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 743 | -613 | 140 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 4734 | 3991 | 4604 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3991 | 4604 | 4464 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 2520 | 713 | 1945 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 1978 | 247 | 1393 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 52030 | 51608 | 52324 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 43896 | 43491 | 44256 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 8134 | 8117 | 8068 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 6695 | 6596 | 6821 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 50591 | 50087 | 51077 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 1 | 1 | 1 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 1438 | 1520 | 1246 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 702 | 863 | 782 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 333 | 447 | 426 |
Usein kysytty kysymys
Mikä on Pharmarise Holdings Corporation (2796.T) taseen loppusumma?
Pharmarise Holdings Corporation (2796.T) kokonaisvarat ovat 23421000000.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.156.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on 152.963.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.006.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.026.
Mikä on Pharmarise Holdings Corporation (2796.T) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 333000000.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 9138000000.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 6695000000.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.